Utsikt
Senior Member (Voting Rights)
Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome
Abstract
(Line breaks added)
BACKGROUND:
There is no established treatment for chronic fatigue syndrome (CFS), an illness characterized by disabling fatigue exacerbated by physical activity. A variety of immunologic abnormalities have been reported, including a high incidence of atopy and hypoergy or anergy.
OBJECTIVE:
Because of anecdotal reports and uncontrolled trials showing antihistamine efficacy in CFS, we evaluated the clinical efficacy of the antihistamine terfenadine (60 mg twice daily) in a placebo-controlled study.
METHODS:
Thirty patients with CFS were enrolled in a 2-month, double-blind, placebo-controlled trial of terfenadine.
Participants underwent a battery of both immediate- and delayed-type hypersensitivity skin tests and completed a self-assessment questionnaire used to measure severity of symptoms, physical and social functioning, health perceptions, and mental health before each of six biweekly visits.
RESULTS:
Twenty-eight patients completed the trial. History of atopy and positive immediate skin test results were prevalent, 73% and 53%, respectively. No evidence for hypoergy or anergy after delayed-type hypersensitivity skin testing was found.
No therapeutic benefit from terfenadine could be detected in terms of symptom amelioration, improved physical or social functioning, health perceptions, or mental health. A high incidence of atopy in patients with CFS was confirmed.
CONCLUSION:
Although this trial involved a small number of patients, the results suggest that terfenadine is unlikely to be of clinical benefit in treating CFS symptoms.
Web | DOI | Journal of Allergy and Clinical Immunology
Steinberg, Paul; McNutt, Bruce E.; Marshall, Paul; Schenck, Carlos; Lurie, Nicole; Pheley, Alfred; Peterson, Phillip K.
Abstract
(Line breaks added)
BACKGROUND:
There is no established treatment for chronic fatigue syndrome (CFS), an illness characterized by disabling fatigue exacerbated by physical activity. A variety of immunologic abnormalities have been reported, including a high incidence of atopy and hypoergy or anergy.
OBJECTIVE:
Because of anecdotal reports and uncontrolled trials showing antihistamine efficacy in CFS, we evaluated the clinical efficacy of the antihistamine terfenadine (60 mg twice daily) in a placebo-controlled study.
METHODS:
Thirty patients with CFS were enrolled in a 2-month, double-blind, placebo-controlled trial of terfenadine.
Participants underwent a battery of both immediate- and delayed-type hypersensitivity skin tests and completed a self-assessment questionnaire used to measure severity of symptoms, physical and social functioning, health perceptions, and mental health before each of six biweekly visits.
RESULTS:
Twenty-eight patients completed the trial. History of atopy and positive immediate skin test results were prevalent, 73% and 53%, respectively. No evidence for hypoergy or anergy after delayed-type hypersensitivity skin testing was found.
No therapeutic benefit from terfenadine could be detected in terms of symptom amelioration, improved physical or social functioning, health perceptions, or mental health. A high incidence of atopy in patients with CFS was confirmed.
CONCLUSION:
Although this trial involved a small number of patients, the results suggest that terfenadine is unlikely to be of clinical benefit in treating CFS symptoms.
Web | DOI | Journal of Allergy and Clinical Immunology